FDA Grants Orphan Drug Status to Tazemetostat for Soft Tissue Sarcoma

June 21, 2017 – Epizyme announced today that the FDA has granted orphan drug designation to its EZH2-inhibitor tazemetostat for the treatment of adults with INI1-negative epithelioid sarcoma. The designation gives the company market exclusivity for soft tissue sarcomas beyond Epizyme’s intellectual property protection and grants access to certain development incentives. The orphan drug designation program is reserved for the safe and effective … (leggi tutto)